Result of AGM

By , in PR PR Sci/Tech on .

Fri, May 18, 2018 18:30 CET

18 May 2018 17:30 BST

Results of Annual General Meeting held on 18 May 2018

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 – 8 were passed as ordinary resolutions and resolutions 9 – 13 were passed as special resolutions.

RESOLUTION VOTES FOR % OF VOTES CAST VOTES AGAINST % OF VOTES CAST VOTES CAST IN TOTAL TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL VOTES WITHHELD
1 To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2017 975,352,556 99.97 286,020 0.03 975,638,576 77.03% 2,190,628
2 To confirm dividends 973,207,907 99.66 3,276,414 0.34 976,484,321 77.09% 1,345,238
3 To reappoint PricewaterhouseCoopers LLP as Auditor 975,991,837 99.92 823,912 0.08 976,815,749 77.12% 1,010,316
4 To authorise the Directors to agree the remuneration of the Auditor 975,217,035 99.83 1,642,984 0.17 976,860,019 77.12% 966,821
5a To re-elect Leif Johansson as a Director 965,159,252 98.78 11,893,311 1.22 977,052,563 77.14% 777,040
5b To re-elect Pascal Soriot as a Director 976,561,635 99.96 423,451 0.04 976,985,086 77.13% 840,934
5c To re-elect Marc Dunoyer as a Director 966,288,665 98.93 10,404,129 1.07 976,692,794 77.11% 1,131,405
5d To re-elect Geneviève Berger as a Director 969,536,507 99.27 7,178,145 0.73 976,714,652 77.11% 1,111,156
5e To re-elect Philip Broadley as a Director 976,367,428 99.97 321,290 0.03 976,688,718 77.11% 1,137,091
5f To re-elect Graham Chipchase as a Director 881,989,499 92.80 68,391,901 7.20 950,381,400 75.03% 27,446,864
5g To elect Deborah DiSanzo as a Director 976,385,364 99.97 318,846 0.03 976,704,210 77.11% 1,122,657
5h To re-elect Rudy Markham as a Director 963,170,539 98.61 13,530,376 1.39 976,700,915 77.11% 1,129,638
5i To elect Sheri McCoy as a Director 976,377,268 99.97 302,558 0.03 976,679,826 77.11% 1,148,061
5j To elect Nazneen Rahman as a Director 975,580,506 99.89 1,085,775 0.11 976,666,281 77.11% 1,161,656
5k To re-elect Shriti Vadera as a Director 974,721,822 99.80 1,938,806 0.20 976,660,628 77.11% 1,168,365
5l To re-elect Marcus Wallenberg as a Director 728,805,452 77.48 211,832,691 22.52 940,638,143 74.26% 37,189,833
6 To approve the Annual Report on Remuneration for the year ended 31 December 2017 616,320,491 65.08 330,706,327 34.92 947,026,818 74.77% 30,798,857
7 To authorise limited political donations 951,435,712 97.85 20,941,516 2.15 972,377,228 76.77% 5,450,018
8 To authorise the Directors to allot shares 879,235,003 90.02 97,511,636 9.98 976,746,639 77.11% 1,081,345
9 To authorise the Directors to disapply pre-emption rights 964,350,714 98.99 9,859,917 1.01 974,210,631 76.91% 3,617,671
10 To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments 948,470,583 97.36 25,722,825 2.64 974,193,408 76.91% 3,633,732
11 To authorise the Company to purchase its own shares 964,157,201 98.76 12,138,730 1.24 976,295,931 77.08% 1,532,147
12 To reduce the notice period for general meetings 887,046,924 91.22 85,341,411 8.78 972,388,335 76.77% 5,438,953
13 To adopt new Articles of Association 962,268,146 99.00 9,709,546 1.00 971,977,692 76.74% 5,848,152

AstraZeneca is pleased to have received shareholder support for all resolutions proposed at the AGM, but is disappointed with the lower level of support received for its Annual Report on Remuneration for the year ended 31 December 2017.

AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to Remuneration Report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result.

The Remuneration Committee has already engaged with a number of shareholders to understand the reasoning behind their decisions not to support the Remuneration Report and will continue to engage with shareholders during 2018 to determine how best to address their concerns.

Issued capital

As at 16 May 2018, the number of issued shares of the Company was 1,266,635,735 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

Adrian Kemp
Company Secretary, AstraZeneca PLC

18 May 2018

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Gonzalo Viña UK/Global +44 203 749 5916
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance; Fixed Income; M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology; Other +1 240 477 3771
Christer Gruvris Brilinta; Diabetes +44 203 749 5711
Nick Stone Respiratory; Renal +44 203 749 5716
US toll free +1 866 381 7277

This information is provided by RNS

The company news service from the London Stock Exchange

The following two tabs change content below.
Maria Burns

Maria Burns

Maria is a Viral News Editor who graduated from the University Of California. She likes social media trends, being semi-healthy, Buffalo Wild Wings and vodka with lime. When she isn’t writing, Maria loves to travel. She last went to Thailand to play with elephants and is planning a trip to Bali.
%d bloggers like this: